A revised Cancer Drugs Fund (CDF) together with wider changes in the way the National Institute for Health and Care Excellence (NICE) assesses cancer drugs has recently been launched. Developed through a partnership between National Health Service (NHS) England and NICE, the new CDF allows drugs which meet set criteria under a managed access agreement between NHS England and pharmaceutical companies to be made available to all eligible patients for up to two years until longer term data are collected. Thereafter, the drug will be moved out of the CDF and considered for routine commissioning on the NHS or made available on an exception basis only.